Aurigene offer diverse solutions to all your medicinal chemistry research requirements, providing the right blend of innovation, vigour, expertise and thorough knowledge of the various aspects of discovery research. With a very experienced scientific team with a 1:6 PhD to MSc ratio and a leadership team with a collective experience of >200 years, together with our experience in handling complex synthetic chemistry problems and our in-house collection of >50000 chemicals, we are ready to rapidly initiate any chemistry programs from our collaborators. We are well versed in all aspects of medicinal chemistry projects, including novel areas like carbohydrates and steroids, PROTACs and molecular glues, oligonucleotides etc.
With a combination of 600+ highly skilled scientists and a state-of-the-art infrastructure spanned over two sites at Bangalore and Hyderabad, we provide the best-in-class medicinal chemistry services to various biotech, pharmaceutical and agrochemical companies. We offer flexible business models like FFS in addition to the usual FTE mode of collaboration, in addition to offering a variety of mix and match programs like chemistry CRO programs together with DMPK or in vitro Biology programs.
Multiple design or route options and complete design to delivery support
Capability across wide chemistry platforms
Library synthesis across various platforms
Lab facilities operating from two locations: Hyderabad and Bangalore
Service in all areas of drug discovery and development
JUNE 28, 2022
Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...Read More
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...Read More
We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...Read More
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.